Last $14.97 USD
Change Today +0.20 / 1.35%
Volume 676.8K
OCUL On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 09/30/14 All times are local (Market data is delayed by at least 15 minutes).

ocular therapeutix inc (OCUL) Snapshot

Open
$14.97
Previous Close
$14.77
Day High
$15.60
Day Low
$14.55
52 Week High
08/28/14 - $16.97
52 Week Low
07/31/14 - $11.90
Market Cap
319.2M
Average Volume 10 Days
146.4K
EPS TTM
--
Shares Outstanding
21.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for OCULAR THERAPEUTIX INC (OCUL)

Related News

No related news articles were found.

ocular therapeutix inc (OCUL) Related Businessweek News

No Related Businessweek News Found

ocular therapeutix inc (OCUL) Details

Ocular Therapeutix, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology for treating eye diseases and conditions. The company offers ReSure Sealant, a synthetic ocular sealant in sealing clear corneal incisions following cataract surgery. Its products also include Dexamethasone Punctum Plug, a drug-eluting punctum plug; Travoprost Punctum Plug or the treatment of glaucoma and ocular hypertension; Moxifloxacin Punctum Plug for the treatment of bacterial conjunctivitis; and posterior segment injections. Ocular Therapeutix, Inc. was founded in 2006 and is headquartered in Bedford, Massachusetts.

52 Employees
Last Reported Date: 07/25/14
Founded in 2006

ocular therapeutix inc (OCUL) Top Compensated Officers

Founder, Chairman, Chief Executive Officer an...
Total Annual Compensation: $254.9K
Chief Operating Officer
Total Annual Compensation: $362.5K
Executive Vice President of Clinical, Regulat...
Total Annual Compensation: $321.5K
Compensation as of Fiscal Year 2013.

ocular therapeutix inc (OCUL) Key Developments

Ocular Therapeutix, Inc. Presents at The 21st Annual NewsMakers in the Biotech Industry 2014, Sep-26-2014 09:30 AM

Ocular Therapeutix, Inc. Presents at The 21st Annual NewsMakers in the Biotech Industry 2014, Sep-26-2014 09:30 AM. Venue: Millennium Broadway Hotel & Conference Center, 145 West 44th Street, New York, New York, United States. Speakers: Amarpreet Sawhney, Founder, Chairman, Chief Executive Officer and President.

Ocular Therapeutix, Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-10-2014 09:45 AM

Ocular Therapeutix, Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-10-2014 09:45 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Amarpreet Sawhney, Founder, Chairman, Chief Executive Officer and President.

Ocular Therapeutix, Inc. Reports Unaudited Earnings Results for the Three Months and Six Months Ended June 30, 2014; Provides Anticipated Clinical Milestones and Development Plans for the Fourth Quarter of 2014

Ocular Therapeutix, Inc. reported unaudited earnings results for the three months and six months ended June 30, 2014. For the three months, the company's revenue was $97,000. Loss from operations was $5,946,000 compared to $2,989,000 a year ago. Net loss attributable to common stockholders was $6,397,000 or $2.10 per basic and diluted share compared to $3,099,000 $1.19 per basic and diluted share a year ago. The company reported a sharply wider net loss for Second Quarter ended June 30 due to increased non-cash charges and operating expenses during the period. For the six months, the company's revenue was $124,000. Loss from operations was $12,771,000 compared to $6,049,000 a year ago. Net loss attributable to common stockholders was $13,411,000 or $4.54 per basic and diluted share compared to $6,307,000 $2.45 per basic and diluted share a year ago. The company provided anticipated clinical milestones and development plans for the fourth quarter of 2014. During the fourth quarter of 2014, the company intends to initiate a Phase 2b clinical trial of OTX-TP for the treatment of glaucoma and ocular hypertension. During the fourth quarter of 2014, Ocular expects to release Phase 2 clinical trial data of OTX-DP for the treatment of chronic allergic conjunctivitis. A total of 60 patients have been randomized 1:1 to receive either OTX-DP or a proprietary placebo punctum plug, using a Modified Conjunctival Allergen Challenge Model (CAC(TM)). OTX-DP is administered as a one-time sustained release corticosteroid with a four-week release. Primary endpoints of the Phase 2 trial include ocular itching and conjunctival redness.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OCUL:US $14.97 USD +0.20

OCUL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OCUL.
View Industry Companies
 

Industry Analysis

OCUL

Industry Average

Valuation OCUL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 362.7x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 1,653.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OCULAR THERAPEUTIX INC, please visit www.ocutx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.